Curis, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET

Company Participants

Diantha Duvall - Chief Financial Officer
Jim Dentzer - President & Chief Executive Officer
Jonathan Zung - Chief Development Officer

Conference Call Participants

Ed White - H.C. Wainwright
Billal Jahangiri - Truist Securities
Daniel Bronder - Cantor
Sean McCutcheon - Raymond James

Operator

Good morning, ladies and gentlemen, and welcome to the Curis Third Quarter 2024 Business Update Call. At this time, all lines are in a listen-only-mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Thursday, November 14, 2024.

I would now like to turn the conference over to Diantha Duvall, Curis's Chief Financial Officer. Please go ahead.

Diantha Duvall

Thank you, and welcome to Curis' third quarter 2024 business update call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com to find our third quarter 2024 business update press release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based upon our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings.

Joining me on today's call are Jim Dentzer, President and Chief Executive Officer; and Jonathan Zung, Chief Development Officer. We will also be available for a question-and-answer period at the end of the call.

I'd now like to turn the call over to Jim.

Jim Dentzer

Thank you, Diantha. Good morning, everyone, and welcome to Curis' third quarter business update call. Let's start with our TakeAim Leukemia Study, which is evaluating emavusertib in combination with ibrutinib in relapsed/refractory PCNSL patients that have failed after treatment with a BTK inhibitor. These patients are generally treated with a methotrexate-based regimen, which includes chemo or radiation in the frontline setting, followed by a BTK inhibitor when a patient's disease progresses. It's when this treatment fails in the salvage line setting that patients become eligible to enroll in our study and receive emavusertib in combination, excuse me, with ibrutinib.

The thesis for this combination, which is supported by both preclinical data and our early clinical data, is that blocking both of the pathways driving NHL, blocking the TLR pathway with emavusertib and blocking the BCR pathway with ibrutinib can enable patients to achieve an objective response even after they've progressed on ibrutinib.